Three-year follow-up of Coats disease treated with conbercept and 532-nm laser photocoagulation

Table 1 Clinical characteristics of the study participants

Case no.	Sex/age in yr/eye	Stage	Comorbidity	Alcohol/smoking status	Quadrants of telangiectasia	No. of injections	No. of laser therapies	BCVA baseline	BCVA 1 wk	BCVA 1 mo	BCVA 3 mo	BCVA 6 mo	BCVA 9 mo	BCVA 12 mo	BCVA 24 mo	BCVA 36 mo	Termination
1	M/31/os	2A	None	Smoker	3	2	1	60	70	68	75	75	74	72	66	65	65
2	M/35/os	2A	None	Drinker	2	1	1	55	70	75	70	70	70	75	80	76	76
3	M/45/od	2A	HTN.	Drinker	2	1	1	28	40	45	50	53	55	55	53	55	55
4	M/29/os	2A	None	None	3	1	2	39	55	65	60	58	60	60	58	62	62
5	M/33/od	2B	None	None	3	2	1	55	70	70	75	75	75	77	75	75	75
6	F/32/od	2B	None	None	3	2	2	70	78	75	78	78	80	80	77	75	75
7	M/35/os	2B	None	Drinker	3	3	2	56	70	75	78	75	75	78	75	75	75
8	M/37/od	2A	Cervical spondylosis	Smoker	2	1	1	54	72	74	77	77	77	78	77	77	77

BCVA: Best-corrected visual acuity; HTN.: Hypertension; os: Oculus sinister; od: Oculus dexter.

Table 2 Best-corrected visual acuity

Time of measurement	Best-corrected visual acuity	P (vs pretreatment value)
Pretreatment	52.12 ± 12.93
1 wk after treatment	65.63 ± 12.19	< 0.001
1 mo after treatment	68.38 ± 10.17	< 0.001
3 mo after treatment	70.38 ± 10.18	< 0.001
6 mo after treatment	70.13 ± 9.42	< 0.001
9 mo after treatment	70.75 ± 8.75	< 0.001
12 mo after treatment	71.88 ± 9.28	< 0.001
24 mo after treatment	70.13 ± 9.98	< 0.001
36 mo after treatment	70.01 ± 8.23	< 0.001
	P-trendlinear < 0.001

Data are presented as mean ± standard deviation.